Skip to content

Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Neuromechanical Characterization of Agonist and Antagonist Muscle Activations in the Lower Limbs During Walking After Central Nervous System Injury

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06107556
Acronym
NEUROGAIT
Enrollment
100
Registered
2023-10-30
Start date
2023-10-19
Completion date
2024-06-30
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spasticity/Paresis, Stroke, Walking, Difficulty

Brief summary

The retrospective study investigates the part of responsibility of neuromuscular disorders associated with chronic hemiparesis in walking impairment.

Detailed description

After injury to the central nervous system, walking disorders are associated with complex neuromuscular mechanisms that alter the direction and intensity of the descending control, reflex reactions to kinematic changes and the mechanical components of soft tissues. The dissociated analysis of these mechanisms and their interactions during multi-segmental movements and especially during walking is poorly described. However, a quantified assessment of the responsibility of each of the neuromuscular mechanisms in the functional disorder would guide the choice of treatments. 3D gait laboratories provide kinematic data from synchronized walking to surface electromyograms as part of additional assessments to assist in the follow-up of patients with chronic hemiparesis. Retrospective analysis of these data would help to better characterize muscular activation disorders and passive resistance to movement during walking in this population.

Interventions

DIAGNOSTIC_TESTGait analysis

3D gait analysis with electromyographic measurements

Sponsors

Henri Mondor University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult * Person who performed tridimensional gait analysis in laboratory * Person who had a stroke at least 6 months before the gait analysis

Exclusion criteria

* Any other neurological pathology or gait disorders * Botulinum toxin injection in the last 3 months before the gait analysis

Design outcomes

Primary

MeasureTime frameDescription
Coefficient of antagonist activation1 yearThe coefficient of antagonist activation of gastrocnemius medialis and soleus was calculated from EMG data by the ratio between the root mean square amplitude during antagonist effort and maximal agonist effort for the same muscle.

Countries

France

Contacts

Primary ContactEmilie Hutin, Ph.D.
emilie.hutin@aphp.fr0149812549
Backup ContactEmilie Hutin
emilie.hutin@aphp.fr0149812549

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026